Lavanya Rayapu, Kajal Chakraborty* and Lokanatha Valluru* Pages 789 - 801 ( 13 )
Background: Diabetes Mellitus (DM) is a major chronic metabolic disorder characterized by hyperglycemia that leads to several complications such as retinopathy, atherosclerosis, nephropathy, etc. In 2019, it was estimated that about 463 million people had diabetes, and it may increase up to 700 million in 2045. Marine macroalgae are the rich source of bioactive compounds for the treatment of diabetes mellitus.
Objective: This review summarizes the recent epidemiology and possible use of marine macroalgae-derived bioactive compounds for the protection against chronic metabolic disease, diabetes mellitus and marine macroalgae as a nutraceutical supplement.
Conclusion: The present therapies available for diabetes treatment are oral medicines and insulin injections. But continuous use of synthetic medicines provides low therapeutic with many side effects. In continuing search of anti-diabetic drugs, marine macroalgae remain as a promising source with potent bioactivity. Among existing marine algae, red and brown algae are reported to show anti-diabetic activity. Hence, the present review focuses on the epidemiology, diabetes biomarkers and different secondary bioactive compounds present in marine macroalgae to treat diabetes mellitus.
Diabetes mellitus, brown marine algae, red marine algae, metabolic disorder, hyperglycemia, anti-diabetic drugs.
Department of Biotechnology, Dravidian University, Kuppam-517426, A.P, Marine Biotechnology Division, Central Marine Fisheries Research Institute (CMFRI), Ernakulum, Cochin-682001, Kerala, Department of Biotechnology, Dravidian University, Kuppam-517426, A.P